Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DS-2325a MAD in healthy subjects
NCT05583669Phase 1Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Nov 2022
- Primary completion
- May 2023
- Modality
- Gene Editing, Gene Silencing, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Netherton syndrome (NS) comparing DS-2325a with Placebo (2 arms). Primary endpoint: Number of Participants with Any Treatment-emergent Adverse Events. Started Nov 2022; status: completed.
02
Drugs
DS-2325a
03
Conditions
Netherton syndrome (NS)
Beyond the preview
Go deeper on NCT05583669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05583669.